Lorena Rodríguez, M.D.

This newsletter provides information about the FDA's recent approval of iloperidone to treat bipolar I disorder in adults. It discusses the drug's effectiveness, recommended dosages, and potential adverse effects. We also share key points from an interview on the principles of psychodynamic psychopharmacology, a presentation on the evidence supporting the application of TMS in the treatment of various psychiatric disorders and its potential side effects, and our practical research summaries of child, adolescent, and adult psychiatry.